Introduction and Objective: The prevalence of type 1 diabetes (T1D) in older adults has increased over the last few decades. Many aspects of self-care may be impacted by age related changes, comorbidities, and risk of hypoglycemia. Yet, few studies have characterized the emotional burden of diabetes distress (DD) in this age group and its clinical impacts, including association with glycemic control.Methods: We conducted a post-hoc analysis of baseline data from a randomized, multicenter trial of 82 older adults (≥65 yrs). DD was measured by T1-DDS questionnaires that includes overall score and 7 subscales. Scores were dichotomized into mild or no DD (0-1.9) vs. moderate to severe DD (≥2). All participants used study continuous glucose monitor.Results: The baseline characteristics of 82 participants are demonstrated in table. A total of 23 participants (28%) had moderate to severe overall DD; 30 (36.5%) had moderate to severe hypoglycemia distress (subscale). Older adults with elevated DD spent more time <70 mg/dL as compared to those with mild or no DD.Conclusion: The prevalence of moderate to severe DD in older adults was lower than what has been reported for younger adults with T1D (42%). Though association between DD and hyperglycemia (specifically HbA1c) has been observed in younger population, these data suggest that DD may be associated with increased hypoglycemia and glycemic variability in older adults.
S. Rizvi: None. R.J. Henderson: None. L. Kanapka: None. A. Kahkoska: None. C. Reid: None. D. Desjardins: None. N. Chaytor: None. R.S. Weinstock: Research Support; Amgen Inc, Eli Lilly and Company, Tandem Diabetes Care, Inc, Diasome Pharmaceuticals, Insulet Corporation, MannKind Corporation, Dexcom, Inc. M.R. Rickels: Consultant; Vertex Pharmaceuticals Incorporated, Sernova, Corp. Research Support; Dompé, Tandem Diabetes Care, Inc. Consultant; Novo Nordisk. R.E. Pratley: Consultant; AbbVie Inc. Stock/Shareholder; Altanine, Inc. Consultant; Amgen Inc, AstraZeneca. Other Relationship; Bayer AG, Bayer Pharmaceuticals, Inc, Biomea Fusion. Consultant; Boehringer-Ingelheim. Other Relationship; Carmot Therapeutics, Inc, Corcept Therapeutics, Dompé, Eli Lilly and Company, Endogenex. Consultant; Endogenex. Other Relationship; Fractyl Health, Inc., Gasherbrum Bio, Inc. Consultant; Genprex, Getz Pharma, Hanmi Pharm. Co., Ltd, Intas Pharmaceuticals Ltd, Lexicon Pharmaceuticals, Inc, Lilly USA LLC. Speaker’s Bureau; Lilly USA LLC. Other Relationship; Metavention, Novo Nordisk, Novo Nordisk. Speaker’s Bureau; Novo Nordisk. Other Relationship; Pfizer Inc, Poxel SA. Consultant; Regeneron Pharmaceuticals. Other Relationship; Sanofi. Consultant; Scholar Rock. Other Relationship; Sun Pharmaceutical Industries Ltd. Y.C. Kudva: Advisory Panel; Novo Nordisk, Vertex Pharmaceuticals Incorporated, Tandem Diabetes Care, Inc. Research Support; Dexcom, Inc., Insulet Corporation.
R01DK122603
Source link
Leave a Reply